In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $30.00. The company's shares closed last Tuesday at $12.76. According to TipRanks.com, Syed 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.1% and a 35.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $23.58 average price target.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-coherus-biosciences-chrs?utm_source=advfn.com&utm_medium=referral
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Coherus BioSciences Charts.